These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
149 related articles for article (PubMed ID: 6118205)
21. [Incidence of the deficit form in refractory schizophrenia]. Samuelian JC Encephale; 1996 Jun; 22 Spec No 2():19-23. PubMed ID: 8767037 [TBL] [Abstract][Full Text] [Related]
22. [Neuroleptic malignant syndrome and atypical antipsychotics: a brief review]. Khaldi S; Kornreich C; Choubani Z; Gourevitch R Encephale; 2008 Dec; 34(6):618-24. PubMed ID: 19081460 [TBL] [Abstract][Full Text] [Related]
23. [Treatment of schizophrenia]. Houy-Durand E; Thibaut F Rev Prat; 2002 Jun; 52(11):1213-20. PubMed ID: 12148207 [TBL] [Abstract][Full Text] [Related]
24. Withdrawal symptoms after long-term treatment with low-potency neuroleptics. Chouinard G; Bradwejn J; Annable L; Jones BD; Ross-Chouinard A J Clin Psychiatry; 1984 Dec; 45(12):500-2. PubMed ID: 6150030 [TBL] [Abstract][Full Text] [Related]
26. Drug treatment of schizophrenia. Hollister LE Psychiatr Clin North Am; 1984 Sep; 7(3):435-52. PubMed ID: 6148741 [TBL] [Abstract][Full Text] [Related]
27. [Current data on neurologic sequelae caused by neuroleptics]. Krebs MO Encephale; 1995 Jun; 21 Spec No 3():49-52. PubMed ID: 7628342 [TBL] [Abstract][Full Text] [Related]
28. Atypical neuroleptics in the treatment of early onset schizophrenia. Masi G Panminerva Med; 1997 Sep; 39(3):215-21. PubMed ID: 9360425 [TBL] [Abstract][Full Text] [Related]
29. New drugs for schizophrenia: an update for family physicians. Amadio PB; Cross LB; Amadio P Am Fam Physician; 1997 Sep; 56(4):1149-56, 1159-60. PubMed ID: 9310066 [TBL] [Abstract][Full Text] [Related]
31. [Non-extrapyramidal motor side-effects in long-term therapy with neuroleptics: an analysis of 99 patients]. Ginzel I; Hilger E; Barnas C Wien Klin Wochenschr; 2002 Jan; 114(1-2):38-43. PubMed ID: 12407934 [TBL] [Abstract][Full Text] [Related]
32. [Profile of the action of neuroleptics in deficit schizophrenia]. Vanelle JM Encephale; 1996 Jun; 22 Spec No 2():33-9. PubMed ID: 8767040 [TBL] [Abstract][Full Text] [Related]
33. The future of neuroleptic psychopharmacology. Ortiz A; Gershon S J Clin Psychiatry; 1986 May; 47 Suppl():3-11. PubMed ID: 2871013 [TBL] [Abstract][Full Text] [Related]
34. Iron modulates neuroleptic-induced effects related to the dopaminergic system. Ben-Shachar D; Livne E; Spanier I; Zuk R; Youdim MB Isr J Med Sci; 1993 Sep; 29(9):587-92. PubMed ID: 7901181 [TBL] [Abstract][Full Text] [Related]
35. Adverse effects of risperidone and haloperidol treatment in schizophrenia. Yen YC; Lung FW; Chong MY Prog Neuropsychopharmacol Biol Psychiatry; 2004 Mar; 28(2):285-90. PubMed ID: 14751424 [TBL] [Abstract][Full Text] [Related]
36. New antipsychotic agents and the future. Mackay AV J Clin Psychiatry; 1985 Apr; 46(4 Pt 2):51-3. PubMed ID: 2858482 [TBL] [Abstract][Full Text] [Related]
38. Pharmacology of neuroleptics in use in the United States. Richelson E J Clin Psychiatry; 1985 Aug; 46(8 Pt 2):8-14. PubMed ID: 2862140 [TBL] [Abstract][Full Text] [Related]
39. [Role of long-acting neuroleptics in the treatment of schizophrenia]. Levine J; Schooler NR; Cassano G Encephale; 1979; 5(3):285-90. PubMed ID: 39740 [TBL] [Abstract][Full Text] [Related]